ES2545667T3 - Agente reductor del colesterol sérico o agente preventivo o terapéutico para el tratamiento de la aterosclerosis - Google Patents

Agente reductor del colesterol sérico o agente preventivo o terapéutico para el tratamiento de la aterosclerosis Download PDF

Info

Publication number
ES2545667T3
ES2545667T3 ES04746153.8T ES04746153T ES2545667T3 ES 2545667 T3 ES2545667 T3 ES 2545667T3 ES 04746153 T ES04746153 T ES 04746153T ES 2545667 T3 ES2545667 T3 ES 2545667T3
Authority
ES
Spain
Prior art keywords
cholesterol lowering
agent
preventive
atherosclerosis
lowering agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES04746153.8T
Other languages
English (en)
Inventor
Hiroshi Tomiyama
Masayuki Yokota
Kazuhiro Kosakai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kotobuki Seiyaku Co Ltd
Original Assignee
Kotobuki Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kotobuki Seiyaku Co Ltd filed Critical Kotobuki Seiyaku Co Ltd
Application granted granted Critical
Publication of ES2545667T3 publication Critical patent/ES2545667T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Un agente reductor del colesterol sérico o agente preventivo o terapéutico para la aterosclerosis consistente en la combinación de un compuesto representado por la siguiente fórmula química o una sal farmacéuticamente aceptable del mismo y un inhibidor de la biosíntesis del colesterol y/o un agente reductor del colesterol de tipo fibrato, donde dicho inhibidor de la biosíntesis del colesterol es al menos un inhibidor de la HGM CoA reductasa seleccionado entre el grupo consistente en atorvastatina y rosuvastatina y dicho agente reductor del colesterol de tipo fibrato es fenofibrato.**Fórmula**

Description

imagen1
imagen2
imagen3
imagen4

Claims (1)

  1. imagen1
ES04746153.8T 2003-06-27 2004-06-15 Agente reductor del colesterol sérico o agente preventivo o terapéutico para el tratamiento de la aterosclerosis Active ES2545667T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003185171A JP2005015434A (ja) 2003-06-27 2003-06-27 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
JP2003185171 2003-06-27
PCT/JP2004/008678 WO2005000353A1 (ja) 2003-06-27 2004-06-15 血清コレステロール低下剤或はアテローム性動脈硬化症の予防又は治療剤

Publications (1)

Publication Number Publication Date
ES2545667T3 true ES2545667T3 (es) 2015-09-14

Family

ID=33549648

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04746153.8T Active ES2545667T3 (es) 2003-06-27 2004-06-15 Agente reductor del colesterol sérico o agente preventivo o terapéutico para el tratamiento de la aterosclerosis

Country Status (16)

Country Link
US (1) US7795229B2 (es)
EP (1) EP1655037B1 (es)
JP (1) JP2005015434A (es)
KR (1) KR100792098B1 (es)
CN (1) CN1812812B (es)
AU (1) AU2004251536B2 (es)
BR (1) BRPI0411723B1 (es)
CA (1) CA2529452C (es)
DK (1) DK1655037T3 (es)
ES (1) ES2545667T3 (es)
HK (1) HK1095733A1 (es)
MX (1) MXPA05014084A (es)
NO (1) NO335222B1 (es)
PT (1) PT1655037E (es)
RU (1) RU2328307C2 (es)
WO (1) WO2005000353A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
CA2550215A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
CN101243072A (zh) 2005-06-20 2008-08-13 先灵公司 用作组胺h3拮抗剂的哌啶衍生物
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
MY148538A (en) 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
EP0877750B1 (en) 1995-10-31 2002-06-19 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic a gents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
SI1593670T1 (sl) 2000-12-20 2007-12-31 Schering Corp S hidroksi substituirani 2-azetidinoni, uporabni kot sredstva za zniĹľevanje holesterola
HUP0303915A3 (en) * 2001-01-26 2012-12-28 Merck Sharp & Dohme Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
KR20040025889A (ko) * 2001-01-26 2004-03-26 쉐링 코포레이션 혈관성 질환을 치료하기 위한 스테롤 흡수 억제제와심혈관성 제제의 조합물
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same

Also Published As

Publication number Publication date
CN1812812B (zh) 2010-11-03
EP1655037A4 (en) 2010-04-28
BRPI0411723B1 (pt) 2016-08-02
AU2004251536A1 (en) 2005-01-06
DK1655037T3 (en) 2015-08-24
NO20060366L (no) 2006-01-23
NO335222B1 (no) 2014-10-20
MXPA05014084A (es) 2006-03-17
KR100792098B1 (ko) 2008-01-04
US7795229B2 (en) 2010-09-14
RU2006102355A (ru) 2006-07-27
AU2004251536B2 (en) 2007-11-15
RU2328307C2 (ru) 2008-07-10
CN1812812A (zh) 2006-08-02
PT1655037E (pt) 2015-10-19
US20060154876A1 (en) 2006-07-13
CA2529452A1 (en) 2005-01-06
JP2005015434A (ja) 2005-01-20
CA2529452C (en) 2011-02-15
EP1655037B1 (en) 2015-08-05
KR20060012032A (ko) 2006-02-06
EP1655037A1 (en) 2006-05-10
BRPI0411723A (pt) 2006-08-08
WO2005000353A1 (ja) 2005-01-06
HK1095733A1 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
ES2545667T3 (es) Agente reductor del colesterol sérico o agente preventivo o terapéutico para el tratamiento de la aterosclerosis
ES2545205T3 (es) Combinación de azelastina y ciclesonida
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
ES2545076T3 (es) Uso del inhibidor de HDAC panobinostat para el tratamiento de mieloma
ES2485867T3 (es) Compuestos opioides de carboxamido
EP2266981A3 (en) Benzothiazole compounds useful as kinase inhibitors
RU2008139905A (ru) Фармацевтическая композиция для наружного применения
CO5720995A2 (es) Compuesto novedoso
RU2489151C3 (ru) Фармацевтическая комбинация, содержащая ингибитор sglt2
CO5580767A2 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
DE50015163D1 (de) Verwendung von r-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxy-methyl-Phenylisobuttersäureester Hydrogenfumarat zur Behandlung von Harndrang-Inkontinenz und anderen spasmogenen Leiden
ES2531660T3 (es) Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
ATE289590T1 (de) Beta-sulfonyl-hydroxamsäuren als matrix- metalloproteinaseinhibitoren
DK0931788T3 (da) Metalloproteasehæmmere
ES2196190T3 (es) Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico.
DE60310916D1 (de) Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
NO20054787D0 (no) Indenderivater som farmasotiske midler
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
ATE354622T1 (de) Flüssigkristallines medium
AR040078A1 (es) Diaminotiazoles
BRPI0412636A (pt) imidazopirimidinas substituìdas para a prevenção e tratamento de cáncer
RU2009138470A (ru) Композиция для наружного применения на коже
AR043327A1 (es) Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes
MXPA04009421A (es) Compuestos de tiazol-2-ilimina como inhibidores de la pde-7.
JP2006509753A5 (es)